E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 7/29/2016 in the Prospect News PIPE Daily.

Innovus completes $3 million placement of $3.3 million convertibles

Discounted promissory notes sold with 3 million five-year warrants

By Devika Patel

Knoxville, Tenn., July 29 – Innovus Pharmaceuticals, Inc. sold another $828,889 of convertible promissory notes at a 10% original issue discount for $750,000 in a private placement on July 25, according to an 8-K filed Friday with the Securities and Exchange Commission. Rodman & Renshaw was the agent for the offering, which sold $2.48 million of notes for $2.25 million on July 5 and July 15.

The 5% notes are due on July 30, 2017. They convert to common stock at $0.25 per share, a 13.64% premium to $0.22, the July 1 closing share price.

The investors also received warrants for 3 million shares. Each five-year warrant is exercisable at $0.40, an 81.82% premium to the July 1 closing share price.

Proceeds will be used for general working capital purposes.

The pharmaceutical company is based in Sierra Madre, Calif.

Issuer:Innovus Pharmaceuticals, Inc.
Issue:Convertible promissory notes
Amount:$3,303,889
Maturity:July 30, 2017
Price:10% original issue discount ($3 million)
Coupon:5%
Conversion premium:13.64%
Conversion price:$0.25
Warrants:For 2.25 million shares
Warrant expiration:Five years
Warrant strike price:$0.40
Agent:Rodman & Renshaw
Settlement dates:July 5 and July 15 ($2,475,000 of notes for $2.25 million), July 25 ($828,889 of notes for $750,000)
Stock symbol:OTCBB: INNV
Stock price:$0.22 at close July 1
Market capitalization:$23.08 million

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.